| Michael J Naunczek, MD | |
|
1301 N 5th St, Perkasie, PA 18944-2200 | |
| (215) 257-5128 | |
| Not Available |
| Full Name | Michael J Naunczek |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 1301 N 5th St, Perkasie, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902859010 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD062935L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grand View Home Care | Sellersville, PA | Home health agency |
| Grand View Hospital | Sellersville, PA | Hospital |
| St Lukes Quakertown Hospital | Quakertown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trivalley Primary Care Pc | 4981680923 | 55 |
News Archive
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute's capabilities for studying and treating lung cancer.
Boston University School of Medicine researchers may have found a way to delay or even prevent Alzheimer's disease (AD). They discovered that pre-treatment of neurons with the anti-aging protein Klotho can prevent neuron death in the presence of the toxic amyloid protein and glutamate.
Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
The National Institutes of Health announced today that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS).
› Verified 2 days ago
| Entity Name | Northwestern Medical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806003 PECOS PAC ID: 8729987243 Enrollment ID: O20040105000322 |
News Archive
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute's capabilities for studying and treating lung cancer.
Boston University School of Medicine researchers may have found a way to delay or even prevent Alzheimer's disease (AD). They discovered that pre-treatment of neurons with the anti-aging protein Klotho can prevent neuron death in the presence of the toxic amyloid protein and glutamate.
Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
The National Institutes of Health announced today that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS).
› Verified 2 days ago
| Entity Name | Trivalley Primary Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245295757 PECOS PAC ID: 4981680923 Enrollment ID: O20040629000657 |
News Archive
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute's capabilities for studying and treating lung cancer.
Boston University School of Medicine researchers may have found a way to delay or even prevent Alzheimer's disease (AD). They discovered that pre-treatment of neurons with the anti-aging protein Klotho can prevent neuron death in the presence of the toxic amyloid protein and glutamate.
Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
The National Institutes of Health announced today that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael J Naunczek, MD 1301 N 5th St, Perkasie, PA 18944-2200 Ph: (215) 257-5128 | Michael J Naunczek, MD 1301 N 5th St, Perkasie, PA 18944-2200 Ph: (215) 257-5128 |
News Archive
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute's capabilities for studying and treating lung cancer.
Boston University School of Medicine researchers may have found a way to delay or even prevent Alzheimer's disease (AD). They discovered that pre-treatment of neurons with the anti-aging protein Klotho can prevent neuron death in the presence of the toxic amyloid protein and glutamate.
Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
The National Institutes of Health announced today that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS).
› Verified 2 days ago
Amy H Moeller, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1301 N 5th St, Perkasie, PA 18944 Phone: 215-257-5128 | |
David C Moll, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1301 N 5th St, Perkasie, PA 18944 Phone: 215-257-5128 |